PERSEPT 3 A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta recombinant human FVIIa in perioperative care in subjects with haemophilia A or B with inhibitors

Simple item page
dc.citation.doi10.1111/HAE.14418
dc.citation.epage920
dc.citation.spage911
dc.contributor.authorM Escobar
dc.contributor.authorJ Luck
dc.contributor.authorY Averianov
dc.contributor.authorJ Ducore
dc.contributor.authorM Fernandez
dc.contributor.authorJohnny Mahlangu
dc.date.accessioned2023-04-13T10:23:29Z
dc.date.available2023-04-13T10:23:29Z
dc.identifier.citationWOS
dc.identifier.issn1351-8216
dc.identifier.urihttps://hdl.handle.net/10539/35011
dc.journal.titleHAEMOPHILIA
dc.journal.volume1
dc.titlePERSEPT 3 A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta recombinant human FVIIa in perioperative care in subjects with haemophilia A or B with inhibitors
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Journal.pdf
Size:
321.68 KB
Format:
Adobe Portable Document Format
Description:
Journal
Download
Collections
Academic Wits Research Outputs (All submissions)